EVOQ Partners With Gilead On NanoDisc Approach To RA, Lupus

Michigan biotech follows 2021 collaboration in autoimmune disease with Amgen with its second tie-up, teaming up with Gilead in rheumatoid arthritis and systemic lupus erythematosus.

Nanotech
EVOQ's approach involves delivering antigens therapeutically via nanotechnology • Source: Shutterstock

Privately held EVOQ Therapeutics is using a new collaboration in autoimmune disease with Gilead Sciences, Inc., along with a similar partnership inked with Amgen, Inc., to get its NanoDisc delivery technology off the ground. During a 3 January interview to discuss the Gilead tie-up, CEO William Brinkerhoff said EVOQ saw substantial early potential for its platform in cancer but will now be looking at rheumatoid arthritis and systemic lupus erythematosus.

Launched in 2016 with intellectual property in-licensed from nearby University of Michigan, EVOQ uses a platform technology that takes...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.